An interventional study of Bachmann Bundle Pacing and Right Atrial Appendage Pacing in Heart Failure, Atrial Fibrillation (AF) and Cardiac Insufficiency, sponsored by Fu Wai Hospital, Beijing, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Fu Wai Hospital, Beijing, China · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 119th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2026, is one of 115 with no phase, reaches primary completion later than 135 of the 181 other live ones, and was the 345th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 43 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
Fu Wai Hospital, Beijing, China is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Fu Wai Hospital, Beijing, China has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, prospective, single-blind, randomized controlled clinical trial to evaluate the efficacy and safety of Bachmann bundle pacing (BBP) in preventing new-onset atrial fibrillation (AF) in patients with chronic cardiac insufficiency who have indications for cardiac resynchronization therapy with left bundle branch pacing (CRT/LBBP) or implantable cardioverter defibrillator (ICD) implantation.
A total of 110 eligible patients will be randomly assigned 1:1 to the BBP group or the traditional right atrial appendage (RAA) pacing group. All patients will receive guideline-directed medical therapy (GDMT) for at least 3 months and standardized follow-up for 12 months after device implantation. The primary endpoint is the incidence of new-onset AF within 12 months after implantation. Secondary endpoints include time to first new-onset AF, procedural success rate, changes in cardiac function parameters, and incidence of adverse events. This study aims to provide high-level evidence-based medical evidence for BBP as a new atrial pacing strategy to prevent AF in heart failure patients.
Background Chronic heart failure (HF) is a prevalent and prognostically poor cardiovascular disorder, with atrial fibrillation (AF) being the most common arrhythmia comorbid with HF. The bidirectional interaction between HF and AF forms a vicious cycle, significantly elevating the risks of mortality, hospitalization, and stroke in affected patients. Epidemiological data indicate that the cumulative incidence of AF following pacemaker implantation reaches 30-40%, a rate markedly higher than that in the general population without pacemaker implantation.
Traditional right atrial appendage (RAA) pacing, the most widely used clinical atrial pacing approach, induces prolonged interatrial conduction, asynchronous atrial contraction, and hemodynamic perturbations, which predispose patients to AF. The Bachmann bundle represents the most physiological atrial pacing site; pacing in this region achieves synchronous activation of the left and right atria, producing a narrower P wave compared with sinus rhythm and traditional RAA pacing. While prior studies have suggested that Bachmann bundle pacing (BBP) may reduce the recurrence and progression of atrial arrhythmias, there remains a paucity of prospective randomized controlled trials investigating the efficacy of BBP in preventing new-onset AF in HF patients undergoing cardiac resynchronization therapy with left bundle branch pacing (CRT/LBBP) or implantable cardioverter defibrillator (ICD) implantation.
Study Objectives The primary objective of this study is to determine whether BBP reduces the incidence of new-onset AF within 12 months of device implantation, compared with traditional RAA pacing, in HF patients with indications for CRT/LBBP or ICD implantation. Secondary objectives include evaluating the impact of BBP on the time to first new-onset AF, procedural safety, cardiac function parameters, electrophysiological indices, and clinical adverse events (including HF rehospitalization, all-cause death, and stroke) during the 12-month follow-up period.
Study Procedures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive atrial lead implantation at the Bachmann bundle region, identified by anatomical localization and intracardiac electrogram. Successful BBP is defined by characteristic ECG changes (positive P wave in I/II/III/aVF, biphasic/negative P wave in V1, narrowed P wave duration) and recording of Bachmann bundle potential. If BBP fails, patients are converted to RAA pacing, with failure reasons documented.
Procedure: Bachmann Bundle Pacing
Patients receive conventional atrial lead implantation in the right atrial appendage (RAA), the standard clinical atrial pacing method. Intraoperative pacing parameters (threshold, sensing, impedance) are monitored identically to the experimental group to ensure normal pacing function. All patients continue guideline-directed medical therapy for heart failure throughout the study.
Procedure: Right Atrial Appendage Pacing
A minimally invasive endocardial pacing procedure where an atrial lead is placed at the Bachmann bundle region (located at the junction of the right atrium and left atrial appendage) under fluoroscopic and intracardiac electrogram guidance. Successful implantation is confirmed by characteristic ECG changes (positive P wave in leads I/II/III/aVF, biphasic/negative P wave in V1, P wave duration reduction \>10 ms in patients with interatrial block) and recording of the Bachmann bundle potential.
Also known as: BBP
The standard clinical atrial pacing procedure where an atrial lead is implanted in the right atrial appendage via transvenous access, guided by fluoroscopy. Pacing parameters (threshold, sensing, impedance) are optimized intraoperatively to ensure stable atrial capture, consistent with current clinical practice guidelines for cardiac pacing in heart failure patients.
Also known as: RAA Pacing
Incidence of New-Onset Atrial Fibrillation
The proportion of patients who develop new-onset atrial fibrillation (AF) confirmed by 12-lead ECG or 24-hour Holter monitoring within 12 months after cardiac pacing device implantation. New-onset AF is defined as the first documentation of AF with a duration ≥30 seconds in patients with no prior history of AF or paroxysmal AF (documented ≥3 months before enrollment).
Time frame: 12 months after device implantation
Time to Onset of New-Onset Atrial Fibrillation Post-Device Implantation
Time from CRT/LBBP or ICD implantation to the first documentation of new-onset atrial fibrillation (AF) confirmed by 12-lead ECG or 24-hour Holter monitoring, with AF defined as an episode lasting ≥30 seconds. Time is recorded in days and analyzed using Kaplan-Meier survival methods.
Time frame: Up to 12 months after device implantation
Immediate Success Rate of Bachmann Bundle Pacing and Perioperative Complication Rate
Immediate success of Bachmann bundle pacing is defined as stable lead placement with successful atrial capture and characteristic ECG changes intraoperatively; perioperative complications (occurring within 30 days post-surgery) include lead dislodgement, pneumothorax, cardiac tamponade, and pocket hematoma, with incidence calculated as the proportion of patients with at least one complication in each group.
Time frame: Intraoperatively (success rate) and 30 days post-implantation (perioperative complications)
Absolute and percentage change in left atrial diameter/volume index from baseline to 12 months
Absolute and percentage changes in left atrial diameter (mm) and left atrial volume index (mL/m²) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Change in mitral/tricuspid regurgitation grade from baseline to 12 months
Change in mitral and tricuspid regurgitation grade (graded 0-IV) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Absolute change in left ventricular end-diastolic diameter (LVEDD) from baseline to 12 months
Absolute change in LVEDD (mm) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Absolute change in left ventricular end-systolic volume (LVESV) from baseline to 12 months
Absolute change in LVESV (mL) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Change in New York Heart Association (NYHA) functional class from baseline to 12 months
Change in NYHA functional class (graded I-IV) at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Absolute change in 6-minute walk test (6MWT) distance from baseline to 12 months
Absolute change in 6MWT distance (meters) at 12 months post-implantation compared with baseline
Time frame: Baseline and 12 months after device implantation
Absolute change in plasma NT-ProBNP level from baseline to 12 months
Absolute change in plasma NT-ProBNP level (pg/mL) measured by chemiluminescent immunoassay at 12 months post-implantation compared with baseline.
Time frame: Baseline and 12 months after device implantation
Comparison of P-wave duration from baseline to 12 months
Comparison of P-wave duration (ms) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation
Time frame: Baseline and 12 months after device implantation
Comparison of P-wave amplitude from baseline to 12 months
Comparison of P-wave amplitude (mV) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation
Time frame: Baseline and 12 months after device implantation
Comparison of P-wave vector from baseline to 12 months
Comparison of P-wave vector in the supine position between baseline and 12 months post-implantation.
Time frame: Baseline and 12 months after device implantation
Prevalence of interatrial block at baseline and 12 months
Prevalence of interatrial block (diagnosed by ECG criteria) in the supine position between baseline and 12 months post-implantation
Time frame: Baseline and 12 months after device implantation
Comparison of ventricular pacing threshold from baseline to 12 months
Comparison of ventricular pacing threshold (V) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation.
Time frame: Baseline and 12 months after device implantation
Comparison of sensing threshold from baseline to 12 months
Comparison of sensing threshold (mV) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation
Time frame: Baseline and 12 months after device implantation
Comparison of lead impedance from baseline to 12 months
Comparison of lead impedance (Ω) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation.
Time frame: Baseline and 12 months after device implantation
Incidence of Procedure Complications Within 12 Months Post-Implantation
Cumulative incidence of long-term surgical complications (including lead fracture, chronic pocket infection, lead dislodgement, and cardiac perforation) within 12 months post-implantation, with complications adjudicated by an independent committee using VARC-3 criteria for severity and causality.
Time frame: 12 months after device implantation
Incidence of Heart Failure Rehospitalization, All-Cause Death, and Stroke Within 12 Months
Cumulative incidence of heart failure rehospitalization (unplanned admission for worsening HF), all-cause mortality, and ischemic/hemorrhagic stroke within 12 months post-implantation. All events are documented via medical records and confirmed by the study team.
Time frame: 12 months after device implantation
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — The decision to share individual participant data (IPD) is currently undecided and will be reassessed upon completion of the study. Considerations will include compliance with Chinese regulations on medical data privacy, ethical approval requirements for data sharing, and the need to protect participants' confidential health information. A formal IPD sharing plan will be developed if deemed appropriate post-study, in accordance with international clinical research standards.
Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fu Wai Hospital, Beijing, China